Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich type of brain cancer will show significant response to AI-based ROBO1 CAR T cell therapy by end of 2024?
Glioblastoma • 25%
Medulloblastoma • 25%
Astrocytoma • 25%
Other • 25%
Results published in reputable medical journals or official announcements from research institutions
Researchers Develop AI-Based Immunotherapy for Glioblastoma Using ROBO1 CAR T Cells
Aug 2, 2024, 09:09 AM
Researchers are pioneering a new immunotherapy approach using artificial intelligence (AI) to treat glioblastoma, a highly aggressive form of brain cancer. This innovative method, developed by scientists at institutions including Keck School of Medicine at USC and Cambridge University, aims to transform cancer treatment. The approach involves developing AI models to create new tools for combating cancer. A promising therapy treatment has been discovered that can kill glioblastoma cells by targeting a newly-discovered brain pathway, as reported in Nature Medicine. Additionally, the use of ROBO1 CAR T cells has shown potential as a potent immunotherapy for glioblastoma and other invasive brain cancers. This Canadian-developed treatment could significantly impact the fight against the most aggressive brain cancers.
View original story
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Colorectal Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Breast Cancer • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Lymphoma • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Other • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Prostate Cancer • 25%
Colon Cancer • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other • 25%
Brain cancer • 25%
Breast cancer • 25%
Lung cancer • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Improved efficacy • 25%
Reduced side effects • 25%
Lower cost of treatment • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%